[go: up one dir, main page]

ZA200803420B - Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases - Google Patents

Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases

Info

Publication number
ZA200803420B
ZA200803420B ZA200803420A ZA200803420A ZA200803420B ZA 200803420 B ZA200803420 B ZA 200803420B ZA 200803420 A ZA200803420 A ZA 200803420A ZA 200803420 A ZA200803420 A ZA 200803420A ZA 200803420 B ZA200803420 B ZA 200803420B
Authority
ZA
South Africa
Prior art keywords
formulations
jorumycin
safracin
saframycin
proliferative diseases
Prior art date
Application number
ZA200803420A
Other languages
English (en)
Inventor
Calvo Salve Pilar
Tobio Barreira Maria
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of ZA200803420B publication Critical patent/ZA200803420B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200803420A 2005-10-31 2008-04-17 Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases ZA200803420B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0522082.7A GB0522082D0 (en) 2005-10-31 2005-10-31 Formulations

Publications (1)

Publication Number Publication Date
ZA200803420B true ZA200803420B (en) 2009-10-28

Family

ID=35515969

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803420A ZA200803420B (en) 2005-10-31 2008-04-17 Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases

Country Status (23)

Country Link
US (1) US9192568B2 (ru)
EP (1) EP1968592B1 (ru)
JP (1) JP5197373B2 (ru)
KR (1) KR101434230B1 (ru)
CN (1) CN101300011B (ru)
AT (1) ATE549023T1 (ru)
AU (1) AU2006310260C1 (ru)
CA (1) CA2625096C (ru)
DK (1) DK1968592T3 (ru)
ES (1) ES2383967T3 (ru)
GB (1) GB0522082D0 (ru)
HR (1) HRP20120478T1 (ru)
IL (1) IL190774A (ru)
NO (1) NO341057B1 (ru)
NZ (1) NZ567291A (ru)
PL (1) PL1968592T3 (ru)
PT (1) PT1968592E (ru)
RS (1) RS52312B (ru)
RU (1) RU2429845C2 (ru)
SI (1) SI1968592T1 (ru)
UA (1) UA97629C2 (ru)
WO (1) WO2007052076A2 (ru)
ZA (1) ZA200803420B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
KR20110025178A (ko) * 2008-05-16 2011-03-09 파르마 마르 에스.에이. Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법
CN102065865B (zh) * 2008-05-16 2013-03-20 马尔药品公司 多发性骨髓瘤治疗
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
CA2833500C (en) * 2011-04-28 2019-01-08 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
WO2014065751A1 (en) 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US10526334B2 (en) 2017-07-19 2020-01-07 California Institute Of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
US20240197726A1 (en) * 2021-03-03 2024-06-20 The University Of Tokyo Novel tetrahydroisoquinoline alkaloid compound containing macrocycle

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
DE19605212A1 (de) * 1996-02-13 1997-08-14 Basf Ag Phosphordotiertes Silberkatalysator-Festbett
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
EP0983082A1 (en) 1997-05-21 2000-03-08 Genentech, Inc. Novel administration of thrombopoietin
PT1067933E (pt) 1998-04-06 2007-11-15 Univ Illinois Ecteinascidinas semi-sintéticas
CZ302168B6 (cs) 1998-05-11 2010-11-24 Pharma Mar, S. A. Metabolity ecteinascidinu 743
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
AU784249C (en) 2000-04-12 2007-05-03 Pharma Mar S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
AU2001281232A1 (en) 2000-08-11 2002-02-25 City Of Hope The anti-neoplastic agent ET-743 inhibits trans activation by SXR
ES2256305T3 (es) * 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
AU3956502A (en) * 2000-11-03 2002-05-27 Harvard College Saframycins, analogues and uses thereof
SK287901B6 (sk) 2000-11-06 2012-03-02 Pharma Mar, S. A. Use of Ecteinascidin 743 for preparation of medicament for effective antitumor treatment
KR20030071853A (ko) 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 에포틸론 유사체를 함유한 비경구용 제제
EP1360337A1 (en) * 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
WO2002076459A1 (en) 2001-03-06 2002-10-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
JP2005509650A (ja) 2001-10-19 2005-04-14 ファルマ・マール・ソシエダード・アノニマ 癌治療における抗腫瘍化合物の改良した使用
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7251892B2 (en) * 2003-07-09 2007-08-07 Temper Corporation Bearing assembly spacer adjustable system and method for adjusting a spacer
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
CA2544320A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
WO2005118584A2 (en) * 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
EP1768671A2 (en) 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
JP2008514688A (ja) 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
KR101287918B1 (ko) 2004-10-26 2013-07-19 오르토 바이오테크 프로덕츠 엘.피. 엑티나시딘 ７４３과 조합된 페길화된 리포좀 독소루비신
NZ554761A (en) * 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
DE602006020335D1 (de) 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
CA2652035A1 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments

Also Published As

Publication number Publication date
IL190774A0 (en) 2008-11-03
AU2006310260B2 (en) 2012-08-09
KR20080064959A (ko) 2008-07-10
AU2006310260A1 (en) 2007-05-10
KR101434230B1 (ko) 2014-08-26
WO2007052076A2 (en) 2007-05-10
NO20082425L (no) 2008-07-25
GB0522082D0 (en) 2005-12-07
HK1122743A1 (en) 2009-07-17
HRP20120478T1 (hr) 2012-07-31
RU2429845C2 (ru) 2011-09-27
JP2009513618A (ja) 2009-04-02
CA2625096C (en) 2015-11-24
JP5197373B2 (ja) 2013-05-15
ES2383967T3 (es) 2012-06-27
UA97629C2 (ru) 2012-03-12
NO341057B1 (no) 2017-08-14
RU2008121716A (ru) 2009-12-10
US9192568B2 (en) 2015-11-24
SI1968592T1 (sl) 2012-10-30
IL190774A (en) 2013-11-28
PL1968592T3 (pl) 2012-08-31
ATE549023T1 (de) 2012-03-15
WO2007052076A3 (en) 2008-03-20
DK1968592T3 (da) 2012-07-02
AU2006310260C1 (en) 2013-09-19
CA2625096A1 (en) 2007-05-10
US20090076016A1 (en) 2009-03-19
CN101300011B (zh) 2011-12-28
PT1968592E (pt) 2012-06-18
EP1968592B1 (en) 2012-03-14
CN101300011A (zh) 2008-11-05
EP1968592A2 (en) 2008-09-17
RS52312B (sr) 2012-12-31
NZ567291A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
TW200621256A (en) Formulations
ZA200803420B (en) Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases
WO2007061874A3 (en) Methods and compositions for use in treating cancer
TW200801008A (en) Protein kinase inhibitors
WO2009105513A8 (en) Novel compounds and methods for therapy
IN2009DN05670A (ru)
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
MX2011001679A (es) Derivados de flavina.
NO20070782L (no) Tetrapeptidanaloger.
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
WO2005030144A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2007097981A3 (en) Alpha carbolines and uses thereof
TW200640926A (en) Pyrazolopyrimidines
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
IL200000A (en) Process for Preparing 5- (1- Alkylthio) Alkylpyridines are Stored in Position 2 and Its Compounds
PL2059503T3 (pl) Pochodne aminopirazolu, sposób ich wytwarzania oraz kompozycja do zapobiegania lub leczenia chorób niedokrwiennych zawierająca takie pochodne
WO2007120333A3 (en) Tetracyclic kinase inhibitors
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
SG152296A1 (en) Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one